Tags

Type your tag names separated by a space and hit enter

Putranjivain A from Euphorbia jolkini inhibits both virus entry and late stage replication of herpes simplex virus type 2 in vitro.
J Antimicrob Chemother. 2004 Apr; 53(4):577-83.JA

Abstract

AIMS

To investigate the in vitro antiviral properties of putranjivain A, isolated from the whole plant of Euphorbia jolkini Bioss (Euphorbiaceae).

METHODS AND RESULTS

Herpes simplex virus (HSV)-2 strain 196-infected Vero cells were used. It was shown that putranjivain A exhibited antiviral activity with an IC50 of 7.9 +/- 1.2 micro M using the XTT assay, with the IC50 value increasing with increasing multiplicity of infection. Using the plaque reduction assay, the IC50 and IC90 were 6.3 +/- 0.8 and 14.5 +/- 3.1 micro M, respectively. Putranjivain A showed no cytotoxic effect on cell multiplication at concentrations that achieved antiviral activity. The 50% cell cytotoxic concentration (CC50) was 80.3 +/- 14.7 microM, and the selectivity index (SI) (ratio of CC50 to IC50) for the XTT and plaque reduction assays was 10.2 and 12.7, respectively. When tested for virucidal activity, putranjivain A significantly reduced viral infectivity at concentrations of 75 and 100 micro M, but not at 50 microM or below. The results of the time-of-addition studies suggested that putranjivain A affected the late stage of HSV-2 replication at 25 microM. Interestingly, putranjivain A also showed inhibition of viral attachment and cell penetration. The combination of putranjivain A and aciclovir produced no interaction.

CONCLUSIONS

Putranjivain A possesses antiviral activity, inhibiting viral attachment and penetration, and also interfering with the late stage of viral replication.

Authors+Show Affiliations

Cheng HY
Graduate Institute of Pharmaceutical Sciences, College of Pharmacy, Kaohsiung Medical University, Kaohsiung.
Lin TC
No affiliation info available
Yang CM
No affiliation info available
Wang KC
No affiliation info available
Lin LT
No affiliation info available
Lin CC
No affiliation info available

MeSH

AnimalsAntiviral AgentsChlorocebus aethiopsDose-Response Relationship, DrugEuphorbiaGallic AcidGlucosidesHerpesvirus 2, HumanPlant ExtractsPlant StructuresVero CellsVirus Replication

Pub Type(s)

Journal Article

Language

eng

PubMed ID

14998984

Citation

Cheng, Hua-Yew, et al. "Putranjivain a From Euphorbia Jolkini Inhibits Both Virus Entry and Late Stage Replication of Herpes Simplex Virus Type 2 in Vitro." The Journal of Antimicrobial Chemotherapy, vol. 53, no. 4, 2004, pp. 577-83.
Cheng HY, Lin TC, Yang CM, et al. Putranjivain A from Euphorbia jolkini inhibits both virus entry and late stage replication of herpes simplex virus type 2 in vitro. J Antimicrob Chemother. 2004;53(4):577-83.
Cheng, H. Y., Lin, T. C., Yang, C. M., Wang, K. C., Lin, L. T., & Lin, C. C. (2004). Putranjivain A from Euphorbia jolkini inhibits both virus entry and late stage replication of herpes simplex virus type 2 in vitro. The Journal of Antimicrobial Chemotherapy, 53(4), 577-83.
Cheng HY, et al. Putranjivain a From Euphorbia Jolkini Inhibits Both Virus Entry and Late Stage Replication of Herpes Simplex Virus Type 2 in Vitro. J Antimicrob Chemother. 2004;53(4):577-83. PubMed PMID: 14998984.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Putranjivain A from Euphorbia jolkini inhibits both virus entry and late stage replication of herpes simplex virus type 2 in vitro. AU - Cheng,Hua-Yew, AU - Lin,Ta-Chen, AU - Yang,Chien-Min, AU - Wang,Kuo-Chih, AU - Lin,Liang-Tzung, AU - Lin,Chun-Ching, Y1 - 2004/03/03/ PY - 2004/3/5/pubmed PY - 2004/5/29/medline PY - 2004/3/5/entrez SP - 577 EP - 83 JF - The Journal of antimicrobial chemotherapy JO - J Antimicrob Chemother VL - 53 IS - 4 N2 - AIMS: To investigate the in vitro antiviral properties of putranjivain A, isolated from the whole plant of Euphorbia jolkini Bioss (Euphorbiaceae). METHODS AND RESULTS: Herpes simplex virus (HSV)-2 strain 196-infected Vero cells were used. It was shown that putranjivain A exhibited antiviral activity with an IC50 of 7.9 +/- 1.2 micro M using the XTT assay, with the IC50 value increasing with increasing multiplicity of infection. Using the plaque reduction assay, the IC50 and IC90 were 6.3 +/- 0.8 and 14.5 +/- 3.1 micro M, respectively. Putranjivain A showed no cytotoxic effect on cell multiplication at concentrations that achieved antiviral activity. The 50% cell cytotoxic concentration (CC50) was 80.3 +/- 14.7 microM, and the selectivity index (SI) (ratio of CC50 to IC50) for the XTT and plaque reduction assays was 10.2 and 12.7, respectively. When tested for virucidal activity, putranjivain A significantly reduced viral infectivity at concentrations of 75 and 100 micro M, but not at 50 microM or below. The results of the time-of-addition studies suggested that putranjivain A affected the late stage of HSV-2 replication at 25 microM. Interestingly, putranjivain A also showed inhibition of viral attachment and cell penetration. The combination of putranjivain A and aciclovir produced no interaction. CONCLUSIONS: Putranjivain A possesses antiviral activity, inhibiting viral attachment and penetration, and also interfering with the late stage of viral replication. SN - 0305-7453 UR - https://www.unboundmedicine.com/medline/citation/14998984/Putranjivain_A_from_Euphorbia_jolkini_inhibits_both_virus_entry_and_late_stage_replication_of_herpes_simplex_virus_type_2_in_vitro_ DB - PRIME DP - Unbound Medicine ER -